| 41.81 Delayed Data As of Mar 18 |  +0.03 / +0.07%Today’s Change | 34.32 Today|||52-Week Range 46.47 | -4.22% Year-to-Date |
| Previous close | 41.78 |
| Today’s open | 41.77 |
| Day’s range | 41.65 - 42.07 |
| Volume | 18,021,218 |
| Average volume (3 months) | 26,035,762 |
| Market cap | $230.1B |
| Earnings growth (last year) | -11.08% |
| Earnings growth (this year) | -3.84% |
| Earnings growth (next 5 years) | +6.10% |
| Revenue growth (last year) | +2.10% |
| P/E ratio | 22.5 |
| Price/Sales | 4.86 |
| Price/Book | 3.74 |
| Today’s change | Today’s % change | |
|---|---|---|
| NVSNovartis | -0.12 | -0.13% |
| MRKMerck | -0.22 | -0.27% |
| ABTAbbott Laboratories | -1.03 | -1.29% |
| LLYEli Lilly and Co | +1.30 | +1.05% |
| Next reporting date | April 30, 2019 |
| EPS forecast (this quarter) | $0.75 |
| Annual revenue (last year) | $53.6B |
| Annual profit (last year) | $11.2B |
| Net profit margin | 20.77% |
Sector Health Technology |
Industry Pharmaceuticals: Major |
Director, Chief Executive & Operating Officer Albert Bourla |
Chief Financial Officer & EVP-Business Operations Frank A. D'Amelio |
Corporate headquarters New York, New York |
